CORONA Remedies Ltd. (CORONA) Share Price Hits New 52-Week High
- August 3, 2026
- Posted by: Harsh Piplani
- Category: News
CORONA Remedies Ltd. Share Price reached a new 52-week high of Rs 2,112.9, marking a 0.73% increase today. The market cap stands at Rs 12,828.94 crore.
CORONA Remedies Ltd. Share Price has reached a new 52-week high of Rs 2,112.9, reflecting a 0.73% increase from the previous close of Rs 2,097.6. The stock opened at Rs 2,180 and reached a high of Rs 2,208.05 during the day. The market capitalisation of the company is Rs 12,828.94 crore. This milestone highlights the company’s recent performance in the market, drawing attention from investors and analysts alike.
CORONA Remedies Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,112.9 |
| Previous Close | Rs 2,097.6 |
| Today's Change | +Rs 15.3 (+0.73%) |
| Day Open | Rs 2,180 |
| Fresh 52-Week High | Rs 2,208.05 |
| Day Low | Rs 2,055 |
| Current Volume | 2,044 |
| Turnover | Rs 0.43 crore |
| Market Capitalisation | Rs 12,828.94 crore |
CORONA Remedies Ltd. (CORONA) traded at Rs 2,112.9. versus the previous close of Rs 2,097.6, a rise of 0.73%. The stock opened at Rs 2,180, reached Rs 2,208.05, touched Rs 2,055. Reported volume was 2,044.
Today’s trading session saw CORONA Remedies Ltd. reaching a fresh 52-week high of Rs 2,208.05. The stock opened at Rs 2,180 and fluctuated between a low of Rs 2,055 and a high of Rs 2,208.05. The current price stands at Rs 2,112.9, with a day change of Rs 15.3, equivalent to a 0.73% increase. The turnover for the day was Rs 0.43 crore, with a volume of 2,044 shares, indicating moderate trading activity. This price action suggests a positive sentiment among investors, leading to the new yearly high.
CORONA Remedies Ltd. (CORONA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 12,828.94 crore |
| P/E Ratio | 30.09x |
| P/B Ratio | 0.44x |
| ROE | -2.89% |
| ROCE | -0.26% |
CORONA Remedies Ltd. was valued at a P/E ratio of 30.09x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 30.09x |
| Benchmark Median P/E | 20.73x |
| Benchmark Average P/E | 67.98x |
| Benchmark P/E Range | 0x to 3,417.8x |
| Company P/B Ratio | 0.44x |
| Benchmark Median P/B | 1.91x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.7% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.13% |
| Company Market Capitalisation | Rs 12,828.94 crore |
| Benchmark Median Market Cap | Rs 130.49 crore |
CORONA Remedies Ltd. (CORONA) is classified under sector: Healthcare.
CORONA Remedies Ltd. (CORONA) has a P/E ratio of 30.09x, which is above the benchmark median of 20.73x, a difference of +45.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
CORONA Remedies Ltd. (CORONA) has a ROE of -2.89%, which is below the benchmark median of 10.7%, a difference of -127.01%. CORONA Remedies Ltd. (CORONA) has a ROCE of -0.26%, which is below the benchmark median of 13.13%, a difference of -101.98%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,931.84 | 30.09 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,683.28 | 39.84 | 8.11 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,474.26 | 59.65 | 7.97 | 18.65 | 22.17 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,416.82 | 169.49 | 3.13 | 13.9 | 12.97 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,414 | 34.44 | 6.97 | -2.6 | 16.92 |
CORONA Remedies Ltd. (CORONA) has a P/E ratio of 30.09x compared with the displayed peer median of 39.84x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. CORONA Remedies Ltd. (CORONA) has a market capitalisation of Rs 12,828.94 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching CORONA Remedies Ltd.
- Reached a new 52-week high of Rs 2,112.9
- Moderate trading activity with a turnover of Rs 0.43 crore
- Higher P/E ratio compared to sector median
- Significant market cap within the healthcare sector
- Negative profitability ratios indicating potential challenges
About CORONA Remedies Ltd.
CORONA Remedies Ltd. is a prominent player in the healthcare sector, focusing on the development and distribution of pharmaceutical products. The company operates across various segments, catering to diverse medical needs. With a significant market presence, CORONA Remedies Ltd. continues to expand its portfolio and enhance its market position within the competitive healthcare landscape.
Track CORONA Remedies Ltd. Share Price on Univest
Use CORONA Remedies Ltd. (CORONA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track the live share price of CORONA Remedies Ltd., along with technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay updated with the latest stock news and analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of CORONA Remedies Ltd.?
Ans. The current share price of CORONA Remedies Ltd. is Rs 2,112.9, marking a 0.73% increase from the previous close of Rs 2,097.6. The stock moved 0.73% during the session. The intraday range extended from Rs 2,055 to Rs 2,208.05.
What is CORONA Remedies Ltd.'s market capitalisation?
Ans. CORONA Remedies Ltd. has a market capitalisation of Rs 12,828.94 crore, positioning it as a significant player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.09x.
How does CORONA Remedies Ltd.'s P/E ratio compare to the sector?
Ans. CORONA Remedies Ltd.'s P/E ratio of 30.09 is above the sector median of 20.73, indicating a relatively higher valuation compared to its peers. The company trades at a P/E ratio of 30.09x.
What are the profitability ratios of CORONA Remedies Ltd.?
Ans. CORONA Remedies Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, suggesting challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%.
What was the 52-week high for CORONA Remedies Ltd.?
Ans. The 52-week high for CORONA Remedies Ltd. was Rs 2,208.05, achieved during the current trading session. The stock moved 0.73% during the session. The intraday range extended from Rs 2,055 to Rs 2,208.05.
How does CORONA Remedies Ltd.'s market cap compare to its peers?
Ans. CORONA Remedies Ltd.'s market cap of Rs 12,828.94 crore is significantly higher than its peers, such as Dishman Carbogen Amcis Ltd. and Kwality Pharmaceuticals Ltd. The company operates in the Healthcare sector.
What is the P/B ratio of CORONA Remedies Ltd.?
Ans. CORONA Remedies Ltd. has a P/B ratio of 0.44, which is significantly lower than the sector median of 1.91, indicating a potentially undervalued position. The company trades at a P/E ratio of 30.09x.
How does CORONA Remedies Ltd.'s ROE compare to the sector?
Ans. CORONA Remedies Ltd.'s ROE of -2.89% is below the sector median of 10.7%, indicating lower profitability compared to its peers. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.7%.
